[CLSTR]
< Back to situations

[ORGANIZATION]

Agência Nacional de Vigilância Sanitária (Anvisa)

Featured in 18 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

249 clusters · 899 sources · last updated

Latest: GLP-1 weight loss medications: Expert insights on common misconceptions

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[ACTIVE] [HEALTH] [BR]

Semaglutide regulatory approvals and pricing in Brazil

7 clusters · 109 sources · last updated

Latest: Mantecorp launches Semavy weight-loss pen in Brazil

Brazil’s National Health Surveillance Agency (Anvisa) has expanded the domestic market for semaglutide, a medication used to treat type 2 diabetes and weight loss. Initially, Anvisa registered five new semaglutide inject

[ACTIVE] [HEALTH] [BR] [PY] [FR]

Brazil ANVISA expands product safety enforcement

31 clusters · 228 sources · last updated

Latest: Brazil combats illegal weight-loss drug market as Anvisa fast-tracks generics

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

[QUIET] [HEALTH] [BR] [PY]

Brazil cannabis-derived CBD regulation

2 clusters · 8 sources · last updated

Latest: Anvisa and Dinavisa sign agreement to combat illegal products

Brazil’s National Health Surveillance Agency (Anvisa) is finalizing new regulations to govern the magistral manipulation of cannabidiol (CBD) preparations. The agency has classified this regulatory work as a priority to

Also covered in